The Impact of Intermittent Fasting on Non-Alcoholic Fatty Liver Disease in Older Adults: A Review of Clinicaltrials.gov Registry

References

• Nguyen MH, Le MH, Yeo YH, et al. Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach. Clin Mol Hepatol. 2022;28(4):841. doi:10.3350/CMH.2022.0239
   PubMed Web of Science ®Google Scholar
• Smith BW, Adams LA. Non-alcoholic fatty liver disease. Crit Rev Clin Lab Sci. 2011;48(3):97–113. doi:10.3109/10408363.2011.596521
   PubMed Web of Science ®Google Scholar
• Burt AD, Lackner C, Tiniakos DG. Diagnosis and assessment of NAFLD: definitions and histopathological classification. Semin Liver Dis. 2015;35(03):207–220. doi:10.1055/S-0035-1562942/ID/JR00799-35
   PubMedGoogle Scholar
• Carr RM, Oranu A, Khungar V. Non-alcoholic fatty liver disease: pathophysiology and management. Gastroenterol Clin North Am. 2016;45(4):639. doi:10.1016/J.GTC.2016.07.003
   PubMed Web of Science ®Google Scholar
• Utzschneider KM, Kahn SE. The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2006;91(12):4753–4761. doi:10.1210/JC.2006-0587
   PubMed Web of Science ®Google Scholar
• Kitade H, Chen G, Ni Y, Ota T. Nonalcoholic fatty liver disease and insulin resistance: new insights and potential new treatments. Nutrients. 2017;9(4):387. doi:10.3390/NU9040387
   PubMed Web of Science ®Google Scholar
• Mooli RGR, Ramakrishnan SK. Liver steatosis is a driving factor of inflammation. Cell Mol Gastroenterol Hepatol. 2022;13(4):1267. doi:10.1016/J.JCMGH.2022.01.007
   PubMed Web of Science ®Google Scholar
• Muhammad A. Non-alcoholic fatty liver disease, an overview. Integr Med a Clin J. 2019;18:42.
   Google Scholar
• Muthiah MD, Cheng Han N, Sanyal AJ. A clinical overview of non-alcoholic fatty liver disease: a guide to diagnosis, the clinical features, and complications—what the non-specialist needs to know. Diabetes Obes Metab. 2022;24(S2):3–14. doi:10.1111/DOM.14521
   PubMedGoogle Scholar
• Mirza MS. Obesity, visceral fat, and NAFLD: querying role of adipokines in the progression of nonalcoholic fatty liver disease. ISRN Gastroenterol. 2011;2011:1–11. doi:10.5402/2011/592404
   Google Scholar
• Chung GE, Oh S, Ahn DW, et al. Effects of additive interactions among obesity, visceral adiposity, and sarcopenia on nonalcoholic fatty liver disease. Sci Rep. 2023;13:1–8. doi:10.1038/s41598-023-30833-3
   PubMed Web of Science ®Google Scholar
• Matsuzaka T, Shimano H. New perspective on type 2 diabetes, dyslipidemia and non‐alcoholic fatty liver disease. J Diabetes Investig. 2020;11(3):532. doi:10.1111/JDI.13258
   PubMed Web of Science ®Google Scholar
• Dharmalingam M, Yamasandhi PG. Nonalcoholic fatty liver disease and type 2 diabetes mellitus. Indian J Endocrinol Metab. 2018;22(3):421. doi:10.4103/IJEM.IJEM_585_17
   PubMedGoogle Scholar
• Vassilatou E. Nonalcoholic fatty liver disease and polycystic ovary syndrome. World J Gastroenterol. 2014;20(26):8351. doi:10.3748/WJG.V20.I26.8351
   PubMed Web of Science ®Google Scholar
• Kelley CE, Brown AJ, Diehl AM, Setji TL. Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. World J Gastroenterol. 2014;20(39):14172. doi:10.3748/WJG.V20.I39.14172
   PubMed Web of Science ®Google Scholar
• Tsai JH, Ferrell LD, Tan V, Yeh MM, Sarkar M, Gill RM. Aggressive non-alcoholic steatohepatitis following rapid weight loss and/or malnutrition. Mod Pathol. 2017;30(6):834. doi:10.1038/MODPATHOL.2017.13
   PubMed Web of Science ®Google Scholar
• Aliasghari F, Izadi A, Gargari BP, Ebrahimi S. The effects of ramadan fasting on body composition, blood pressure, glucose metabolism, and markers of inflammation in NAFLD patients: an observational trial. J Am Coll Nutr. 2017;36(8):640–645. doi:10.1080/07315724.2017.1339644
   PubMed Web of Science ®Google Scholar
• Faris MAI, Jahrami H, Abdelrahim D, Bragazzi N, BaHammam A. The effects of ramadan intermittent fasting on liver function in healthy adults: a systematic review, meta-analysis, and meta-regression. Diabetes Res Clin Pract. 2021;178:108951. doi:10.1016/J.DIABRES.2021.108951
   PubMed Web of Science ®Google Scholar
• Badran H, Elsabaawy M, Sakr A, et al. Impact of Intermittent fasting on laboratory, radiological, and anthropometric parameters in NAFLD patients. Clin Exp Hepatol. 2022;8(2):118. doi:10.5114/CEH.2022.115056
   PubMed Web of Science ®Google Scholar
• Prasetya G, Sapwarobol S. Intermittent fasting during ramadan improves insulin sensitivity and anthropometric parameters in healthy young Muslim men. Am J Lifestyle Med. 2018;15(2):200–206. doi:10.1177/1559827618815430
   PubMedGoogle Scholar
• Arab JP, Candia R, Zapata R, et al. Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review. World J Gastroenterol. 2014;20(34):12182. doi:10.3748/WJG.V20.I34.12182
   PubMed Web of Science ®Google Scholar
• Papandreou D, Andreou E. Role of diet on non-alcoholic fatty liver disease: an updated narrative review. World J Hepatol. 2015;7(3):575. doi:10.4254/WJH.V7.I3.575
   PubMedGoogle Scholar
• Glass LM, Dickson RC, Anderson JC, et al. Total body weight loss of ≥ 10 % is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis. Dig Dis Sci. 2015;60(4):1024–1030. doi:10.1007/S10620-014-3380-3
   PubMed Web of Science ®Google Scholar
• Kargulewicz A, Stankowiak-Kulpa H, Grzymisałwski M. Dietary recommendations for patients with nonalcoholic fatty liver disease. Przeglad Gastroenterol. 2014;9:18. doi:10.5114/PG.2014.40845
   PubMedGoogle Scholar
• Amanullah I, Khan YH, Anwar I, Gulzar A, Mallhi TH, Raja AA. Effect of vitamin e in non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomised controlled trials. Postgrad Med J. 2019;95(1129):601–611. doi:10.1136/POSTGRADMEDJ-2018-136364
   PubMed Web of Science ®Google Scholar
• El Hadi H, Vettor R, Rossato M. Vitamin E as a treatment for nonalcoholic fatty liver disease: reality or myth? Antioxidants. 2018;7(1). doi:10.3390/ANTIOX7010012
   Web of Science ®Google Scholar
• Bril F, Biernacki DM, Kalavalapalli S, et al. Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2019;42(8):1481–1488. doi:10.2337/DC19-0167
   PubMed Web of Science ®Google Scholar
• Della Pepa G, Russo M, Vitale M, et al. Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA. IT randomised trial. Diabetes Res Clin Pract. 2021;178:108984. doi:10.1016/J.DIABRES.2021.108984
   PubMed Web of Science ®Google Scholar
• Blazina I, Selph S. Diabetes drugs for nonalcoholic fatty liver disease: a systematic review. Syst Rev. 2019;8(1):1–13. doi:10.1186/S13643-019-1200-8/TABLES/4
   PubMed Web of Science ®Google Scholar
• Wise J. Pioglitazone seems safe and effective for patients with fatty liver disease and diabetes. BMJ. 2016;353. doi:10.1136/BMJ.I3435
   Google Scholar
• Lian J, Fu J. Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes mellitus: a meta-analysis. Front Endocrinol. 2021;12. doi:10.3389/FENDO.2021.615409
   Google Scholar
• Kulkarni AV, Tevethia HV, Arab JP, et al. Efficacy and safety of obeticholic acid in liver disease—a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2021;45(3):101675. doi:10.1016/J.CLINRE.2021.101675
   PubMed Web of Science ®Google Scholar
• Makri E, Cholongitas E, Tziomalos K. Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease. World J Gastroenterol. 2016;22(41):9039. doi:10.3748/WJG.V22.I41.9039
   PubMed Web of Science ®Google Scholar
• Alorfi NM, Algarni AS. Clinical impact of semaglutide, a glucagon-like peptide-1 receptor agonist, on obesity management: a review. Clin Pharmacol. 2022;14:61–67. doi:10.2147/CPAA.S374741
   PubMed Web of Science ®Google Scholar
• Nevola R, Epifani R, Imbriani S, et al. GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives. Int J Mol Sci. 2023;24(2):24. doi:10.3390/IJMS24021703
   Web of Science ®Google Scholar
• Mantovani A, Targher G. Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic steatohepatitis: new insights from subcutaneous semaglutide. Hepatobiliary Surg Nutr. 2021;10(4):518. doi:10.21037/HBSN-2021-13
   PubMed Web of Science ®Google Scholar
• Wong C, Lee MH, Yaow CYL, et al. Glucagon-like peptide-1 receptor agonists for non-alcoholic fatty liver disease in type 2 diabetes: a meta-analysis. Front Endocrinol. 2021;12:609110. doi:10.3389/FENDO.2021.609110/BIBTEX
   PubMed Web of Science ®Google Scholar
• Zhao J, Bai M, Wei S, Li C, Lv Q, Chen Y. Improvement of non-alcoholic fatty liver disease in mice by intermittent use of a fasting-mimicking diet. Mol Nutr Food Res. 2021;65(23). doi:10.1002/MNFR.202100381
   Web of Science ®Google Scholar
• Memel ZN, Wang J, Corey KE. Intermittent fasting as a treatment for nonalcoholic fatty liver disease: what is the evidence? Clin Liver Dis. 2022;19(3):101. doi:10.1002/CLD.1172
   Google Scholar
• Xu Z, Qin Y, Lv B, Tian Z, Zhang B. Intermittent fasting improves high-fat diet-induced obesity cardiomyopathy via alleviating lipid deposition and apoptosis and decreasing M6A Methylation in the heart. Nutrients. 2022;14. doi:10.3390/NU14020251
   Web of Science ®Google Scholar
• Yuan X, Wang J, Yang S, et al. Effect of intermittent fasting diet on glucose and lipid metabolism and insulin resistance in patients with impaired glucose and lipid metabolism: a systematic review and meta-analysis. Int J Endocrinol. 2022;2022:1–9. doi:10.1155/2022/6999907
   Web of Science ®Google Scholar
• Teong XT, Liu K, Vincent AD, et al. Intermittent fasting plus early time-restricted eating versus calorie restriction and standard care in adults at risk of type 2 diabetes: a randomized controlled trial. Nat Med. 2023;29(4):963–972. doi:10.1038/s41591-023-02287-7
   PubMed Web of Science ®Google Scholar
• Vasim I, Majeed CN, DeBoer MD. Intermittent fasting and metabolic health. Nutrients. 2022;14(3):631. doi:10.3390/NU14030631
   PubMed Web of Science ®Google Scholar
• Ravussin E, Gilmore LA, Redman LM. Calorie restriction in humans: impact on human health. Mol Basis Nutr Aging a Vol Mol Nutr Ser. 2016;677–692. doi:10.1016/B978-0-12-801816-3.00048-0
   Google Scholar
• Rynders CA, Thomas EA, Zaman A, Pan Z, Catenacci VA, Melanson EL. Effectiveness of intermittent fasting and time-restricted feeding compared to continuous energy restriction for weight loss. Nutrients. 2019;11(10):2442. doi:10.3390/NU11102442
   PubMed Web of Science ®Google Scholar
• Gnanou JV, Caszo BA, Khalil KM, Abdullah SL, Knight VF, Bidin MZ. Effects of ramadan fasting on glucose homeostasis and adiponectin levels in healthy adult males. J Diabetes Metab Disord. 2015;14(1). doi:10.1186/S40200-015-0183-9
   PubMedGoogle Scholar
• Antoni R, Johnston KL, Collins AL, Robertson MD. Effects of intermittent fasting on glucose and lipid metabolism. Proc Nutr Soc. 2017;76(3):361–368. doi:10.1017/S0029665116002986
   PubMed Web of Science ®Google Scholar
• Ebrahimi S, Gargari BP, Aliasghari F, Asjodi F, Izadi A. Ramadan fasting improves liver function and total cholesterol in patients with nonalcoholic fatty liver disease. Int J Vitam Nutr Res. 2020;90(1–2):95–102. doi:10.1024/0300-9831/A000442
   PubMed Web of Science ®Google Scholar
• Kersten S. The impact of fasting on adipose tissue metabolism. Biochim Biophys Acta Mol Cell Biol Lipids. 2023;1868(3):159262. doi:10.1016/J.BBALIP.2022.159262
   PubMed Web of Science ®Google Scholar
• Khan MN, Khan SI, Rana MI, Ayyaz A, Khan MY, Imran M. Intermittent fasting positively modulates human gut microbial diversity and ameliorates blood lipid profile. Front Microbiol. 2022;13:2931. doi:10.3389/FMICB.2022.922727/BIBTEX
   Web of Science ®Google Scholar
• Lavallee CM, Bruno A, Ma C, Raman M. The role of intermittent fasting in the management of nonalcoholic fatty liver disease: a narrative review. Nutr. 2022;14:4655. doi:10.3390/NU14214655
   Google Scholar
• Khambu B, Yan S, Huda N, Liu G, Yin XM. Autophagy in non-alcoholic fatty liver disease and alcoholic liver disease. Liver Res. 2018;2(3):112–119. doi:10.1016/J.LIVRES.2018.09.004
   PubMedGoogle Scholar
• Urooj A, Kotebagilu NP, Shivanna LM, Anandan S, Thantry AN, Siraj SF. Effect of ramadan fasting on body composition, biochemical profile, and antioxidant status in a sample of healthy individuals. Int J Endocrinol Metab. 2020;18(4):107641. doi:10.5812/IJEM.107641
   PubMed Web of Science ®Google Scholar
• Yin C, Li Z, Xiang Y, et al. Effect of intermittent fasting on non-alcoholic fatty liver disease: systematic review and meta-analysis. Front Nutr. 2021;8:709683. doi:10.3389/FNUT.2021.709683/FULL
   PubMed Web of Science ®Google Scholar
• Monserrat-Mesquida M, Quetglas-Llabrés M, Abbate M, et al. Oxidative stress and pro-inflammatory status in patients with non-alcoholic fatty liver disease. Antioxidants. 2020;9(8):1–16. doi:10.3390/ANTIOX9080759
   Web of Science ®Google Scholar
• Hardiany NS, Karman AP, Calista ASP, et al. The effect of fasting on oxidative stress in the vital organs of New Zealand white rabbit. Reports Biochem Mol Biol. 2022;11:190. doi:10.52547/RBMB.11.2.190
   PubMed Web of Science ®Google Scholar
• Mohr AE, McEvoy C, Sears DD, Arciero PJ, Sweazea KL. Impact of intermittent fasting regimens on circulating markers of oxidative stress in overweight and obese humans: a systematic review of randomized controlled trials. Adv Redox Res. 2021;3:100026. doi:10.1016/J.ARRES.2021.100026
   Google Scholar
• Faris MAIE, Kacimi S, Al-Kurd RA, et al. Intermittent fasting during ramadan attenuates proinflammatory cytokines and immune cells in healthy subjects. Nutr Res. 2012;32(12):947–955. doi:10.1016/J.NUTRES.2012.06.021
   PubMed Web of Science ®Google Scholar
• Mushtaq R, Akram A, Mushtaq R, Khwaja S, Ahmed S. The role of inflammatory markers following ramadan fasting. Pakistan J Med Sci. 2019;35:77. doi:10.12669/PJMS.35.1.95
   PubMed Web of Science ®Google Scholar